CD3 binding domains

US10066015B2 · kind B2 · utility

Assignee

• AFFIMED GMBH · DE

Inventors

• Eugene Zhukovsky · West Hollywood, US
• Melvyn Little · Büdelsdorf, DE
• Stefan Knackmuss · Plankstadt, DE
• Uwe Reusch · Maikammer, DE
• Kristina Ellwanger · Heidelberg, DE
• Ivica Fucek · Hattersheim, DE
• Michael Weichel · Bischofsheim, DE
• Markus Eser · Mülheim an der Ruhr, DE
• Fionnuala McAleese-Eser · Mülheim an der Ruhr, DE

Key dates

• Filing date: Aug 6, 2015
• Grant date: Sep 4, 2018
• Expiry date: Feb 21, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.